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Abstract
Introduction: Vasculopathy, including altered vasoreactivity and abnormal large vessel biomechanics, is a hallmark of 
systemic sclerosis (SSc). However, the pathogenic link with other aspects of the disease is less clear. To assess the 
potential role of transforming growth factor beta (TGF-β) overactivity in driving these cardiovascular abnormalities, we 
studied a novel transgenic mouse model characterized by ligand-dependent activation of TGF-β signaling in 
fibroblasts.
Methods: The transgenic mouse strain Tβ RIIΔk-fib is characterized by balanced ligand-dependent upregulation of 
TGF-β signaling. Aortic and cardiac tissues were examined with histologic, biochemical, and isolated organ bath 
studies. Vascular and perivascular architecture was examined by hematoxylin and eosin (H&E) and special stains 
including immunostaining for TGF-β1 and phospho-Smad2/3 (pSmad2/3). Confirmatory aortic smooth muscle cell 
proliferation, phenotype, and functional assays, including signaling responses to exogenous TGF-β and endothelin-1, 
were performed. Aortic ring contractile responses to direct and receptor-mediated stimulation were assessed.
Results: Aortic ring contractility and relaxation were diminished compared with wild-type controls, and this was 
associated with aortic adventitial fibrosis confirmed histologically and with Sircol assay. TGF-β1 and pSmad 2/3 
expression was increased in the adventitia and smooth muscle layer of the aorta. Aortic smooth muscle cells from 
transgenic animals showed significant upregulation of TGF-β- responsive genes important for cytoskeletal function, 
such as transgelin and smoothelin, which were then resistant to further stimulation with exogenous TGF-β1. These 
cells promoted significantly more contraction of free floating type I collagen lattices when compared with the wild-
type, but were again resistant to exogenous TGF-β1 stimulation. Aortic ring responses to receptor-mediated 
contraction were reduced in the transgenic animals. Specifically, bosentan reduced endothelin-mediated contraction 
in wild-type animals, but had no effect in transgenic animals, and endothelin axis gene expression was altered in 
transgenic animals. Transgenic mice developed cardiac fibrosis.
Conclusions: The histologic, biochemical, and functional phenotype of this transgenic mouse model of scleroderma 
offers insight into the altered biomechanical properties previously reported for large elastic arteries in human SSc and 
suggests a role for perturbed TGF-β and endothelin activity in this process.
Introduction
Vasculopathy is a key pathologic feature of systemic scle-
rosis (SSc) and leads to important clinical complications
including pulmonary arterial hypertension (PAH), sclero-
derma renal crisis (SRC), and severe Raynaud phenome-
non with digital ischemia and infarction. In this study, we
explored systemic vasculopathy and cardiovascular
abnormalities in a transforming growth factor-beta
(TGF-β)-dependent transgenic mouse model that has
been previously shown to replicate the skin and lung
fibrosis of SSc.
Although many previous studies highlighted microvas-
cular abnormalities in SSc [1], a growing body of evidence
exists for structural and functional abnormalities in the
macrovascular circulation. Altered large vessel vasoreac-
tivity and abnormal biomechanical properties have been
described, including vessel stiffness and elasticity of the
aorta and carotid arteries, and impaired flow-mediated
dilatation in brachial arteries [2-6]. Although arterial
stiffness is usually considered to result in hypertension
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aneurysm, none of these is a prevalent feature in SSc [7].
By analogy, TGF-β overactivity is implicated in the patho-
genesis of hypertensive arteriosclerosis, SSc, and some
inherited vascular diseases that affect aortic structure
and function, including Marfan syndrome and Loeys-
Dietz syndrome [8-11].
We previously described a novel genetically determined
transgenic mouse strain in which ligand-dependent acti-
vation of TGF-β signaling occurs selectively in fibroblasts
(Tβ RIIΔk-fib). Expression of this kinase-deficient type II
TGF-β receptor at low levels facilitates activation of the
endogenous type I TGF-β receptor, at least in part by
increasing levels of wild-type Tβ RII. Downstream conse-
quences include upregulation of TGF-β1 and other gene
products that promote TGF-β activity or activate the
latent TGF-β complex. This results in net activation of
TGF-β signaling. However, in response to TGF-β1, signif-
icant elevation of transgene expression is found. Higher
level transgene expression is inhibitory and blocks signal-
ing. Thus, for transcripts upregulated at early time points
by TGF-β1, a transient response occurs in transgenic
cells, but for transcripts induced at 12 hours when the
transgene is also upregulated, suppression is observed.
High level transgene expression does not suppress the
fibroblast-specific promoter completely, suggesting that
other TGF-β-independent pathways also govern the
activity of this lineage-specific construct. We have
described this as a model of balanced TGF-β upregula-
tion occurring selectively in fibroblasts [12-15].
In the present study, we explored the potential link
between TGF-β overactivity and systemic cardiovascular
features of SSc. Our results show upregulation of TGF-β
signalling pathways and vessel wall fibrosis in the sys-
temic arterial circulation, altered vasoreactivity, and a
TGF-β- activated smooth muscle cell phenotype with
additional perturbation of endothelin axis signaling. Our
work provides support for altered TGF-β activity playing
a pivotal role in vasculopathy in this strain and in SSc.
Materials and methods
Generation of transgenic mice
The generation and characterization of Tβ RIIΔk-fib
transgenic mice were described previously [15]. All ani-
mal procedures were conducted in compliance with insti-
tutional and national guidelines and with ethics
committee approval. Neonatal pups were genotyped by
PCR analysis of genomic DNA extracted from tail-biopsy
specimens, by using primers specific for the β-galactosi-
dase reporter gene (5'-CGGATAAACGGAACTGGAAA-
3' and 5'-TAATCACGACTCGCTGTATC-3') (Sigma-
Genosys, Haverhill, UK).
Histologic analysis
Thoracic aortic and cardiac tissue from sacrificed adult
transgenic and littermate sex-matched wild-type mice
were dissected and immersed in 10% normal saline or
were snap-frozen in liquid nitrogen. Formalin-fixed, par-
affin-embedded composite 3 μm sections were mounted
onto poly-L-lysine-coated slides (VWR, UK) and stained
with H&E, picrosirius red, Elastin van Gieson (EVG),
Masson trichrome, and for immunohistochemistry
according to standard protocols [16]. Primary antibodies
were as follows: CD34 (Abcam, Cambridge, UK); TGF-β1
and pSmad2/3 (Santa Cruz Biotechnology, Santa Cruz,
CA); LAP(TGFβ1) (R&D Biosystems, Minneapolis, MN);
and α-SMA (Sigma-Aldrich, St. Louis, MO). Mounted
sections were viewed with an Axioskop Mot Plus micro-
scope by using Axiovision software (Zeiss, Westlar, Ger-
many). Vessel measurements were quantified using the
same software.
Vascular smooth muscle cell culture
Aortae were dissected, the adventitia stripped, and the
vessel opened longitudinally. After collagenase digestion
(1 mg/ml) for 10 minutes at 37°C applied to the endothe-
lial surface, the remaining smooth muscle cells were
grown by explant culture in standard conditions [17].
Immunostaining revealed >99% α-SMA positivity at day
14. Experiments were performed at passages 3 to 4. Cells
were incubated for 24 hours in serum-free medium
before agonist stimulation with TGF-β1 (4 ng/ml) or
endothelin-1 (ET-1, 100 nmol/L). Cells were harvested
using Buffer RLT (Qiagen, Crawley, UK) containing 10 μl/
ml of 14.3 mmol/L β-ME or Laemmli blue buffer and
stored at -70°C, or seeded into chamber slides for immu-
nostaining.
Immunostaining of vascular smooth muscle cells
Seeded cells were fixed with methanol at -20°C for 15 sec-
onds or paraformaldehyde for 15 minutes and rinsed in
PBS. After serum blocking, the cells were stained for 1
hour at room temperature with α-SMA, anti-smoothelin,
anti-SM22α, or anti-β-galactosidase (Abcam), washed in
PBS, and then incubated with the appropriate secondary
antibody (Vector Laboratories) in PBS for 30 minutes.
The slides were washed, mounted with Vectashield
mounting medium containing DAPI (Vector Laborato-
ries), and examined with an Axioskop Z fluorescence
microscope (Zeiss).
Reporter gene assay
The chemiluminescent β-galactosidase assay Galactolight
Plus (Applied Biosystems, Foster City, CA) was used
according to the manufacturer's instructions. In brief,
equivalent numbers of vSMCs and fibroblasts in 96-well
plates were lysed using the proprietary lysis buffer and
incubated for 10 minutes. Then 10 μl was mixed with 70
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accelerator II was added automatically, and the lumines-
cence was measured after 2 seconds using the Mithras LB
940 luminometer (Berthold, Wildbad, Germany). Assays
were performed in triplicate.
Assay of fibrillar collagen content
Newly synthesized acid-soluble collagens (types I to IV)
from the heart or aorta were quantified by using the Sir-
col colorimetric assay (Biodye Science, Newtownabbey,
UK) according to the manufacturer's instructions and
analyzed using the Mithras LB 940 plate reader. Collagen
concentrations were expressed as milligrams per millili-
ter. Data are expressed as mean ± SEM. Statistical com-
parisons were made by using Student's t test.
Isometric tension measurement in isolated aortic rings
Mice thoracic descending aortae were washed in fresh
Krebs buffer (119 mmol/L NaCl, 4.7 mmol/L KCl, 1.2
mmol/L MgSO4, 1.2 mmol/L KH2PO4, 11 mmol/L glu-
cose, 25 mmol/L NaHCO3, 2.5 mmol/L CaCl2), and the
loose connective tissue removed. Aortae were cut into
paired 2- to 3-mm wide rings, which were mounted on
two hooks in a 7 ml organ bath containing Krebs buffer at
37°C, continuously oxygenated with 95% O2/5% CO2. Iso-
metric tension was measured with force-displacement
transducers (Grass Instruments, Quincy, MA), and digi-
tized using a multichannel recording system (Linton
Instrumentation, Diss, Norfolk, UK) with MP100 acquisi-
tion unit and AcqKnowledge software (Biopac Systems,
Goleta, CA). A resting tension of 500-550 mg was applied
to the rings, which were then allowed to equilibrate for 60
minutes. In this period, tissues were washed out with
Krebs buffer, and the applied tension readjusted at 15-
minute intervals.
After the equilibration period, rings were contracted
with cumulative doses of potassium chloride (KCl; 30
mmol/L and 80 mmol/L) until a stable contraction pla-
teau was reached. Contractile responses were measured
by recording changes in tension (milligrams). After wash-
out, the tissues were allowed to reequilibrate for 30 min-
utes, and contractile dose-response curves were
constructed using cumulative doses of phenylephrine
(PE; 10-9 to 10-4 mol/L) and a stable analogue of throm-
boxane A2 (U46619; 10-10 to 10-4 mol/L) or ET-1 (10-11 to
10-7 mmol/L) with washout and equilibration after each
dose response curve. In the relevant experiments, tissues
were pretreated for 20 minutes with 2 mmol/L bosentan
(a dual endothelin receptor antagonist) before contractile
responses to ET-1 were measured. Data are expressed as
mean ± SEM. A value of P < 0.05 was considered signifi-
cant.
Quantitative RT-PCR
Total RNA was extracted by using the RNeasy minikit
(Qiagen) according to the manufacturer's instructions
and quantified using the Nanodrop ND-8000 spectro-
photometer (Thermo-Scientific, Wilmington, DE). The
minimum 260:280 ratio was 1.90. RNA integrity numbers
ranged from 8.8 to 10, measured on an Agilent 2100 Bio-
analyzer (Agilent Technologies UK Limited, Stockport,
UK); 600 ng of RNA was reverse transcribed using the
Quantitect reverse transcription kit (Qiagen) and diluted
fivefold with tRNA, 0.2 μg/ml. The real-time quantitative
RT-PCR used 2 μl RNA in a 10 μl reaction volume by
using Sensimix NoRef in a SYBR green-based assay
(Quantace, London, UK) on a Rotorgene-6000 (Corbett
Life Sciences, Sydney, Australia) under the following con-
ditions: 95°C for 10 minutes, followed by 40 cycles of
95°C for 15 seconds, 57°C for 10 seconds, and 72°C for 5
seconds. Specific products and absence of primer dimers
were confirmed by melt curve analysis. Copy numbers
and assay efficiencies were derived from known copy
number standard curves. Four stable reference genes:
succinate dehydrogenase complex, subunit A (Sdha);
ribosomal protein L13 (Rpl13); β-actin (ActB); and ubiq-
uitin C (Ubc) were identified by using geNorm, and copy
numbers were corrected using the computed normaliza-
tion factor [18]. Primer sequences, written 5'-3', are refer-
enced where appropriate, assay efficiency and R2 follow:
Sdha fwd TGTTCAGTTCCACCCCACA, rev TCTCCA-
CGACACCCTTCTGT, 0.83, 0.991; Rpl13 fwd CAGT-
GAGATACCACACCAAGGTC, rev
GTGCGAGCCACTTTCTTGT, 1.04, 0.998; ActB fwd
CTAAGGCCAACCGTGAAAAG, rev ACCAGAG-
GCATACAGGGACA, 0.83, 0.999; Ubc fwd GAGTTC-
CGTCTGCTGTGTGA, rev
TCACAAAGATCTGCATCGTCA, 0.93, 0.999; Pai-1
[19], 0.89, 1.000; mCol1a1 [19], 0.80, 0.993; Ctgf [19] 0.91,
0.998; Smtn (smoothelin) fwd CGAGGAGGCTG-
CAACTTTA, rev CTGCGCCATTAGCTGCTT, 0.96,
0.999, ETRA [20] 0.95, 0.999, ETRB [20], 0.94, 0.999, ET-1
fwd ACTTCTGCCACCTGGACATC, rev AGT-
TCTTTTCCTGCTTGGCA, 0.9, 0.999; Tagln fwd GAT-
GGAACAGGTGGCTCAAT, rev
TTCCATCGTTTTTGGTCACA, 0.94, 0.999.
Floating collagen gel cultures
Experiments were performed as described previously
[21]. In brief, 24-well tissue culture plates were precoated
with 2.5% bovine serum albumin (BSA). Trypsinized
smooth muscle cells were suspended in Molecular, Cellu-
lar, and Developmental Biology (MCDB) 131 medium
(Invitrogen, Paisley, UK) and mixed with collagen solu-
tion (one part of 0.2 mol/L N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid [HEPES], pH 8.0; four parts col-
lagen [Vitrogen-100, 3 mg/ml, Cohesion Technologies,
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final concentration of 80,000 cells/ml and 1.2 mg/ml col-
lagen. Collagen/cell suspension (1 ml) was added to each
well. After polymerization, gels were detached from wells
by adding 1 ml of medium with or without TGF-β1 (4 ng/
ml). Contraction of the gel was quantified by loss of gel
weight and decrease in gel diameter over a 24-hour
period. Comparison of collagen gel contraction was per-
formed by using Student's t test. A value of P < 0.05 was
considered statistically significant.
Results
Vascular fibrosis in transgenic mice is associated with 
increased TGF-β expression and signaling
Figure 1a shows representative H&E-stained histologic
sections of thoracic aortae from transgenic animals and
wild-type littermate controls. The architecture of the
medial smooth muscle layer was unchanged in the trans-
genic aortae, but adventitial thickness was increased.
This difference is more apparent when stained with Mas-
son trichrome, shown in Figure 1b, where the increased
collagen content of the transgenic adventitia is demon-
strated. Picrosirius red stain viewed with crossed polar-
ized light shows the thicker yellow collagen fibers seen in
the transgenic aortic tissue compared with the smaller
orange-red fibers seen in the wild-type tissue (Figure 1c).
Serial measurements of adventitial thickness on repre-
sentative wild-type sections showed a mean ± SD of 19.3
± 4.4 μm, and on transgenic sections, 27.37 ± 7.88 μm; P <
0.05. This is associated with attenuation of the smooth
muscle layer, so that the adventitial/smooth muscle layer
ratio is also increased in the transgenic animals (Figure
1g). Elastic van Giesson (EVG) staining revealed no dif-
ferences in elastin distribution (data not shown). The his-
tologic finding of increased adventitial collagen was
confirmed by colorimetric Sircol assay for non-cross-
linked collagen deposition in dissected thoracic aortae
(mean transgenic, 22.5 ± 1.87 mg/ml; mean wild-type,
12.4 ± 0.45 mg/ml, P < 0.05), shown in Figure 1h. Consis-
tent with previous studies that have shown increased
TGF-β1 expression and activity in tissues from this trans-
genic mouse stain, immunostaining for latency-associ-
ated peptide for TGF-β1 (LAP(TGFβ1)) and TGF-β1 was
increased in the aortic adventitia of transgenic animals,
as expected. Increased nuclear translocation of pSmad 2/
3 also occurred in transgenic mice in the smooth muscle
Figure 1 Vascular fibrosis in transgenic mice is associated with increased TGF-β expression and signaling. H&E, Masson trichrome, and picro-
sirius red (viewed under polarized light) staining of wild-type and transgenic thoracic aorta sections (a-c). Smooth muscle layer architecture, elastic 
fibers, and smooth muscle layer are normal in the transgenic animals. However, adventitial collagen content is increased, and fibers are thicker in the 
transgenic animals on Masson trichrome and sirius red staining. LAP(TGF-β1) and free TGF-β1 expression is increased particularly in the adventitia (ar-
rows) but also in smooth muscle cells (d-f). Immunostaining for pSmad2/3 confirms increased nuclear translocation in the transgenic compared with 
the wild-type. Original magnification, ×20; representative images for panels (a-f) from transgenic (n = 6) and wild-type (n = 6) littermate sex-matched 
controls. (g) Serial measurements of adventitial and smooth muscle thickness show transgenic adventitial thickening and smooth muscle layer atten-
uation; summary data are expressed as mean ± SEM. *P < 0.05, from transgenic (n = 6) and wild-type (n = 6) littermate sex-matched controls. (h) Sum-
mary data from measurement of non-crosslinked collagen concentration compared with collagen standards (Sircol assay) show significantly higher 
collagen in transgenic animals compared with wild-type. Data are expressed as mean ± SEM.*P < 0.05, from transgenic (n = 8) and wild-type (n = 8) 
littermate sex-matched controls.
Derrett-Smith et al. Arthritis Research & Therapy 2010, 12:R69
http://arthritis-research.com/content/12/2/R69
Page 5 of 11layers, with a mean of 59.24 ± 6.43% positive nuclei in the
transgenic animals compared with a mean of 39.42 ±
7.74% positive nuclei in the wild-type littermate controls
(measured from 2 high-power fields for each mouse, n =
6 in each group; P < 0.001), confirming activation of
Smad-dependent TGF-β signaling pathways in these cell
lineages. Representative images are shown in Figure 1d-f.
Overall, these results confirm that the increased levels of
TGF-β in the extracellular matrix around large vessels in
this strain activate signaling through TGF-β-dependent
pathways in mesenchymal cell types, including vascular
smooth muscle cells (vSMCs), and that this results in
increased extracellular matrix deposition in vessel walls.
Altered aortic ring vasoreactivity in transgenic mice
To investigate whether the vessel wall fibrosis demon-
strated in Figure 1 was associated with altered large vessel
vasoreactivity in the Tβ RIIΔk-fib strain, we examined
aortic ring responses to vasoactive agonists in isolated
organ bath experiments. To elucidate key pathways that
might be involved in regulating smooth muscle cell con-
traction, we used potassium chloride (KCl), which
directly causes smooth muscle cell contraction, and a
series of specific smooth muscle cell receptor agonists.
Contractile responses to KCl were reduced in transgenic
animals (P < 0.05; Figure 2a and 2b), and these were also
reduced in response to vSMC stimulation with phe-
nylephrine, an α-adrenoreceptor agonist (P < 0.05; Figure
2c), and U46619, a stable thromboxane analogue that acts
through the thromboxane A2 receptor and is a potent
vasoconstrictor in mice (P < 0.05; Figure 2d). The relax-
ation response with the NO donor sodium nitroprusside
after precontraction with U46619 was also reduced in
transgenic mice compared with wild-type (P < 0.05; Fig-
ure 2e). This finding may be confounded by the reduced
contraction achieved by U46619, seen in Figure 2d, but is
consistent with the hypothesis that this strain exhibits
generalized arterial stiffness, and the reduction in
dynamic response provides a clear functional correlate of
this. The histologic changes demonstrated in Figure 1 can
be correlated with the functional changes seen here, and
with the hypothesis of TGF-β- mediated arterial stiffness.
Cultured vascular smooth muscle cells from transgenic 
mice have a TGF-β- activated phenotype
In addition to structural changes with increased fibrous
connective tissue in the aortic wall, we reasoned that our
findings may reflect TGF-β- driven changes in vSMC
properties reflecting an altered microenvironment in
vivo. To explore this, early passage cultured aortic smooth
Figure 2 Altered aortic ring vasoreactivity in transgenic mice. (a) Representative vessel wall tension data from one wild-type (black trace) and 
two transgenic (red traces) aortic rings, showing attenuated contraction to two concentrations of KCl (30 and 80 mmol/L). (b) Summary data for wild-
type (n = 7) and transgenic (n = 9) mice. Transgenic mouse aortae show significantly reduced contractile ability in response to direct stimulation of 
the smooth muscle cells with KCl at both low and high concentrations. (c) Phenylephrine (PE)-induced contraction is attenuated in transgenic aortic 
rings, and (d) U46619-induced (a stable thromboxane analogue) contraction is also reduced in the transgenic animal, plotted in response to cumu-
lative concentrations of ligand. Vessels were obtained from WT (n = 8) and TG (n = 5) mice. (e) Vascular responses of aortic arteries isolated from WT 
(n = 9) and TG (n = 5) mice to cumulative concentrations of sodium nitroprusside (SNP) after preconstriction with U46619, data throughout figure are 
expressed as mean ± SEM; *P < 0.05.
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with TGF-β1 and ET-1, which has been shown to induce
an overlapping cohort of profibrotic genes in other cell
types [22]. No significant difference was found in growth
curves over 48 hours, α-SMA protein expression or dis-
tribution between wild-type vSMCs, or those from trans-
genic animals (data not shown). A quantitative reporter
gene assay for β-galactosidase activity confirmed that
wild-type vSMCs and those from transgenic animals had
equal chemiluminescence and hence that the transgene
was not expressed in these cells. These results were con-
firmed on immunofluorescent staining of vSMCs from
wild-type and transgenic animals, by using transgenic
fibroblasts as a positive control (Figure 3a, b). Smoothelin
gene and protein expression was elevated in cells from
transgenic animals (Figure 3c). This molecular hallmark
of contractile vSMCs was previously reported to be regu-
lated by TGF-β [23]. Although exogenous administration
of TGF-β1 to wild-type cells resulted in upregulation of
smoothelin gene expression, the cells from transgenic
animals did not significantly induce further gene expres-
sion, despite elevated basal expression at comparable lev-
els to TGF-β1-activated wild-type cells. A similar, but
more pronounced pattern was demonstrated for transge-
lin gene expression, another important cytoskeletal com-
ponent in vSMCs, with significantly enhanced baseline
expression in vSMCs from transgenic mice (Figure 3d).
Together, these observations suggest a constitutive acti-
vation of TGF-β- regulated gene expression in vSMCs of
transgenic mice that is analogous to previously reported
abnormalities in expression of TGF-β- regulated genes in
dermal fibroblasts of this mouse strain [12]. These find-
ings are consistent with the immunostaining data for
pSmad2/3 shown in Figure 1f. It is noteworthy that some
other TGF-β- regulated genes less specific to vSMCs did
not show this pattern of overexpression. Thus, Pai-1,
Ctgf, and Col1a1 were not significantly different at RNA
level in cells from transgenic animals when compared
with the wild-type and were equivalently induced by
recombinant TGF-β1. For example, Pai-1 was strongly
induced with recombinant TGF-β1, mean fold change 5.3
times baseline (P < 0.05) in cells from both wild-type and
transgenic animals. Induction by ET-1 was comparable at
5.6- and 6.8-fold, respectively (P < 0.05). These findings
contrast with the results from skin fibroblasts from this
mouse strain, in which these genes were significantly
upregulated, and suggest that whereas some of the
molecular phenotype is shared between fibroblasts and
vSMCs in this transgenic strain, important lineage-spe-
cific differences may exist. This is not surprising, consid-
ering that transgene expression is regulated by a
fibroblast-specific promoter that would be expected to
lead to direct perturbation of TGF-β signaling and
responses in fibroblasts but not in other cell types.
Vascular smooth muscle cells from Tβ RIIΔk-fib transgenic 
mice show enhanced remodeling of floating type I collagen 
gel lattices
Pooled data from a series of independent contraction
assays using type I collagen gel lattices delineated an
important functional effect of this activated phenotype.
Figure 4 shows contraction assays from vSMCs of trans-
genic mice compared with wild-type littermates. vSMCs
from transgenic mice promoted more contraction of free-
floating lattices, resulting in gels of reduced diameter and
weight, consistent with an activated profibrotic pheno-
type. Exogenous TGF-β1 induced further contraction by
wild-type cells, but cells from transgenic animals were
refractory to further induction (Figure 4).
Perturbed endothelin receptor expression and function in 
transgenic vascular smooth muscle cells
Previous work suggested important functional cross-talk
between TGF-β and ET-1 that may be relevant to fibrosis
and potentially important in the pathogenesis of SSc and
its vascular complications. We therefore explored
endothelin-1 (ET-1) and endothelin receptor A (ETRA)
and B (ETRB) mRNA expression in vSMCs with quantita-
tive PCR. As expected from previous reports, expression
of ET-1 and ETRA was noted in wild-type vSMCs, but
very low expression of ETRB (data not shown) was found
[24]. vSMCs from transgenic mice have reduced expres-
sion of ETRA mRNA and protein when compared with
wild-type cells, shown in Figure 5a and 5b. It previously
was reported that treatment of vSMCs with either TGF-
β1 or ET-1 downregulates ETRA expression. Our results
were consistent with this: exogenous administration of
TGF-β or ET-1 to cells from both wild-type and trans-
genic mice further suppressed ETRA mRNA expression
(Figure 5a). The finding of reduced expression of ETRA
in vSMCs is consistent with in vivo upregulation of their
ligands and suggests that fibroblast-derived mediators
may be critical for the development of this altered vSMC
phenotype. No significant differences in ET-1 expression
were seen between vSMC cultures from wild-type or
transgenic mice, consistent with the predominantly
endothelial expression of ET-1.
To investigate the functional consequences of altered
endothelin receptor expression in this transgenic strain,
we measured isometric tension in aortic rings from wild-
type and transgenic animals. Contractile responses to ET-
1 were lower in the transgenic aortae when compared
with the wild-type (Figure 5c). Moreover, a consistent
trend was noted to vasodilation in the transgenic aortae,
which may reflect the altered endothelin receptor A/B
balance in these samples. Pretreatment with a potent
endothelin receptor inhibitor (bosentan) reduced the
responsiveness of wild-type aortic rings to ET-1 but, as
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aortae.
Myocardial fibrosis in TβRIIΔk-fib transgenic mice
Another important manifestation of SSc is interstitial
myocardial fibrosis. In this transgenic strain, we pre-
dicted that myocardial fibrosis would occur and may
reflect an altered in vivo hemodynamic phenotype in this
mouse strain as well as potentially intrinsic fibrosis
within the heart. Indeed, transgenic animals showed evi-
dence of myocardial fibrosis on quantitative measure-
ment of non-cross-linked collagen content and on
picrosirius red staining. These findings are summarized
in Figure 6: picrosirius red stain is viewed with both
bright-field and polarized-light microscopy. No inflam-
matory cell infiltrate was evident on H&E staining, and
findings were similar for the left and right ventricles.
These findings provide evidence that altered aortic
dynamics and altered fibroblast interactions with smooth
muscle or cardiac muscle cells result in cardiac fibrosis.
Figure 3 Cultured vascular smooth muscle cells from transgenic mice have a TGF-β- activated phenotype. (a) Reporter gene assay for β-ga-
lactosidase shows equal chemiluminescence in vSMCs from wild-type and transgenic mice. Transgenic fibroblasts from the same animals were used 
as a positive control. Data are expressed as mean ± SEM; *P < 0.05 from WT (n = 3) and TG (n = 3) animals. (b) β-Galactosidase immunostaining results 
comparing vSMCs and fibroblasts from wild-type and transgenic animals show negative staining in all vSMCs and positive staining only in transgenic 
fibroblasts. Images shown are representative of three independent experiments. (c) vSMCs from transgenic mice show increased expression of 
smoothelin gene by qPCR. Recombinant TGF-β1 induced smoothelin mRNA in wild-type vSMCs, but the response in cells from transgenic mice was 
attenuated. Immunostaining confirms constitutive overexpression of smoothelin in vSMCs from transgenic mice. (d) Data for transgelin, a second 
gene important for vSMC cytoskeletal function, show the same trends. Data are expressed as mean ± SEM; *P < 0.05, **P < 0.001; and are representative 
of three independent experiments examining four littermates for each condition. Original magnification, ×40.
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In this study, we examined the systemic vasculature in a
mouse model of SSc in which the primary defect is fibro-
blast-specific perturbation of TGF-β signaling. We
defined, for the first time in this strain, a structural vascu-
lopathy with adventitial fibrosis and smooth muscle
attenuation in the thoracic aorta and further demon-
strated altered vasoreactivity in isolated vessel prepara-
tions in vitro. Smooth muscle cell cultures show
upregulation of TGF-β- dependent genes, and cardiac
fibrosis is evident. Our work complements earlier studies
of skin and lung fibrosis in this transgenic mouse strain.
Previous studies of cultured cells derived from this
transgenic mouse strain have focused on the properties of
fibroblasts [12]. Exploration of the biochemical and func-
tional properties of vSMCs provides important insight
into the potential pathogenic mechanisms of vascular
fibrosis. The lineage-specific nature of transgene expres-
sion precludes an intrinsic perturbation of TGF-β signal-
ing in vSMCs, as they do not express the nonsignaling
type II TGF-β receptor, confirmed in Figure 3a and 3b.
This explains the greater responsiveness for cardinal
TGF-β-regulated transcripts that we observe in vSMCs
compared with dermal fibroblasts [12]. This is consistent
with balanced upregulation of TGF-β signaling in fibro-
blasts in vitro, whereas the activated phenotype of
explanted vSMCs reflects previous in vivo activation by
extracellular TGF-β. Thus, alterations in vascular smooth
muscle cell function are likely to reflect paracrine effects
mediated by transgenic fibroblasts. This is concordant
with the altered epithelial cell phenotype observed in the
lungs of this mouse strain in our studies of lung fibrosis
[19], which also is attributed to bystander effects of fibro-
blast-dependent increased local levels of active TGF-β
ligand. The alterations in endothelin signaling within the
vSMCs of the Tβ RIIΔk-fib strain are reminiscent of those
seen in SSc fibroblasts, which have low ETRA expression
in the context of high ET-1 levels. Previous work con-
Figure 4 Vascular smooth muscle cells from Tβ RIIΔk-fib mice 
show enhanced remodeling of floating type I collagen gel lattic-
es. vSMCs from transgenic animals promoted more contraction of 
free-floating collagen lattices, resulting in gels of reduced diameter 
and weight when compared with wild-type. Induction by exogenous 
TGF-β1 resulted in further contraction by wild-type cells, but cells from 
transgenic mice were refractory to further induction. Data are ex-
pressed as mean ± SEM;*P < 0.05, **P < 0.001, and are representative of 
three independent experiments examining three littermates for each 
condition.
Figure 5 Perturbed endothelin receptor expression and function 
in vascular smooth muscle cells from transgenic animals. (a, b) 
vSMCs from transgenic mice have reduced expression of ETRA mRNA 
and protein when compared with wild-type cells. Exogenous adminis-
tration of TGF-β or ET-1 to cells from both wild-type and transgenic an-
imals further suppressed ETRA expression. Data are representative of 
three independent experiments examining four littermates for each 
condition and are expressed as mean ± SEM,*P < 0.05, **P < 0.001. (c) 
Vasoconstrictor response of aortic rings to ET-1 was attenuated in 
transgenic mice. Bosentan attenuates the response in both wild-type 
and transgenic mice. Representative data from dose response curves 
of WT (n = 6) and TG (n = 6) aortic rings before (-) and after (+) response 
to 10-8 mol/L ET-1 concentrations, before (-) and after (+) bosentan 2 
μmol/L pretreatment. Data are expressed as mean ± SEM; *P < 0.05.
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TGF-β and ET-1 [25,26] in SSc pathogenesis.
Our findings extend and validate data from other TGF-
β- dependent animal models of SSc. For example a rap-
idly progressive vasculopathy is described in the caveolin-
1 knockout mouse, which occurs in part because of
uncontrolled endothelial proliferation, alterations in
vasomotor tone, and a fibrotic phenotype associated with
increased signaling through the TGF-β axis [27,28], and
second, the Tβ RICA Cre-ER mouse strain in which con-
stitutive activation of the Tβ RI in fibroblasts results in
fibrotic thickening of small vessels in the lung and kidney
but histologically normal large vessels and heart [29]. The
heterozygous TSK-1 mouse, which carries a 30- to 40-kb
genomic duplication in the fibrillin-1 gene, has marked
hyperplasia of loose connective tissue around the tho-
racic aorta [30] and altered aortic hemodynamics ex vivo
suggestive of endothelial dysfunction [31]. These models
allow important investigation into the link between
endothelial cell dysfunction and fibrosis but do not
address the more chronic background vasculopathy that
is a hallmark of SSc and may underlie susceptibility to
important clinical complications, including PAH and
SRC.
In this study, structural and dynamic alterations in large
vessels are evident. Abnormalities in elasticity and com-
pliance are most evident in patients with diffuse cutane-
ous SSc [2,6]. These result in a phenotype of arterial
stiffness, which is usually considered to have independent
predictive value for cardiovascular events. Whether SSc
predisposes to increased atherosclerotic risk remains in
question: some reports exist of increased propensity to
peripheral vascular disease in limited cutaneous SSc, but
an association of coronary artery disease with SSc has not
been consistently demonstrated [7,32,33]. Examination of
the microvascular structure in this model in the future,
particularly within the vascular beds of the lung, kidney,
and dermis, is likely to provide further insight into the
molecular basis of vasculopathy in fibrotic disorders such
as SSc.
Potential mechanistic parallels exist between the Tβ
RIIΔk-fib mouse strain and human Loeys-Dietz syn-
drome, in which mutations in Tβ RI and Tβ RII result in
paradoxical increased expression of TGF-β- regulated
proteins and signaling pathways. The fibroblast-specific
nature of transgene expression is a likely explanation for
the absence of greater phenotypic similarity in this mouse
strain. In animal models of essential hypertension, arte-
rial stiffness does not develop because of structural mod-
ifications of the vessel walls with redistribution of the
mechanical load toward elastic materials. Alterations in
the capacities of these remodeling processes may explain
the spectrum of arterial disease seen in Marfan syn-
drome, Loeys-Dietz syndrome, SSc, and hypertension;
fibrillin and TGF-β metabolism are implicated in all
[11,34,35].
The significance of myocardial fibrosis in the Tβ RIIΔk-
fib strain is unclear. It may result from altered pulmonary
and systemic hemodynamics or as a primary process
from excessive TGF-β due to the genetic defect in the
fibroblasts present within the myocardium. It is possible
that an initial response to altered vascular dynamics
results in increased fibroblast activity in the myocardium
and hence higher expression of the transgene and upreg-
ulation of TGF-β. Autopsy studies have revealed evidence
of myocardial interfascicular fibrosis and contraction-
band necrosis in patients with SSc, and myocardial
involvement is an adverse prognostic feature of this con-
dition [36]. The presence of increased cardiac collagen in
Figure 6 Myocardial fibrosis in Tβ RIIΔk-fib transgenic mice. (a) 
Transgenic animals have significantly higher non-crosslinked collagen 
content when compared with sex-matched littermate controls (n = 
10). Data are expressed as mean ± SEM, *P < 0.05. (b) Picrosirius red 
stains of the left ventricles of WT and TG animals viewed under bright-
field and polarized light microscopy. Transgenic animals have a diffuse 
increase in collagen deposition within the myocardial interstitium. 
Original magnification, ×20, representative images from transgenic (n 
= 6) and wild-type (n = 6) littermate sex-matched controls.
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model.
Limitations of this study include the challenge of
directly extrapolating biochemical and functional results
from a mouse model to a complex multisystem disease
such as SSc. Moreover, it is challenging to separate pri-
mary effects of an alteration of fibroblast-derived TGF-β
from those that are due to altered vascular smooth mus-
cle cell properties. Differences may exist between in vivo
mechanisms and the properties of explanted cells in tis-
sue culture or isolated organ bath preparations, although
this method was selected as it provides one of the most
physiologic platforms for studies of vasoreactivity ex vivo.
As expected from the published literature [37], murine
aortic rings were only weakly responsive to endothelin, in
contrast to vessels from other species. Where the tension
axis falls below zero in Figure 5c, suggesting vasodilation,
we speculate that this relates to unopposed vasodilator
effect of type B endothelin receptors. However, although
consistent, this effect did not reach statistical signifi-
cance. Technical limitations of this study include the need
to perform studies on relatively small numbers of mice
and the measurement of mRNA expression levels that
may not correlate with function or activity of encoded
protein.
Conclusions
In conclusion, our study delineates a TGF-β- dependent
macrovascular phenotype in this transgenic mouse strain
associated with vessel wall fibrosis and altered vSMC
properties, including altered TGF-β and ET-1 responses.
These results provide support for a potential link
between perturbed TGF-β and ET-1 bioactivity and car-
diovascular manifestations of human SSc.
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